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Marquet Minor: Cell Type and Tissue Specific Functions of CD73 
(Under the direction of Natasha Snider) 
CD73 is a ubiquitously expressed glycosylphosphatidylinositol (GPI)-anchored 
glycoprotein that converts extracellular adenosine 5'-monophosphate (AMP) to adenosine. CD73 
couples closely with ecto-apyrase (CD39), which supplies the AMP substrate via sequential 
dephosphorylation of extracellular ATP. CD73-generated adenosine functions in an autocrine 
and paracrine manner to control numerous physiological responses by activating one of four 
subtypes of G-protein-coupled adenosine receptors: A1R, A2AR, A2BR, and A3R.  Missense 
mutations in the CD73-encoding gene NT5E cause the rare, adult-onset vascular disease named 
‘arterial calcifications due to deficiency of CD73’ (ACDC). Aside from direct human disease 
involvement, cellular and animal model studies have revealed key functions of CD73 in tissue 
homeostasis and pathophysiologic responses in the cardiovascular and central nervous system, as 
well as epithelial tissues, including the lung, kidney and liver. This review covers CD73 
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CHAPTER 1: INTRODUCTION 
The enzymatic dephosphorylation of 5´-nucleotides, such as adenosine 5´-
monophosphate (AMP) is widespread across mammalian systems and represents a key step in 
purine salvage pathways to modulate purinergic signaling (Ipata & Balestri, 2013; Zimmermann, 
Zebisch, & Strater, 2012). This catalysis occurs inside the cell or in the extracellular space. The 
major enzyme catalyzing the formation of extracellular adenosine from AMP is ecto-5´-
nucleotidase, encoded by the NT5E gene (Zimmermann et al., 2012). Ecto-5’-nucleotidase was 
named CD73 in 1989 after it was shown that its engagement by specific antibodies induced T 
cell activation (Thompson, Ruedi, Glass, Low, & Lucas, 1989). In this review, we refer to the 
protein as CD73 and the gene as NT5E.  Extracellular adenosine produced by CD73 acts on 
adenosine receptors (A1R, A2AR, A2BR, and A3R) to activate downstream signaling (Antonioli, 
Blandizzi, Pacher, & Hasko, 2013; Chen, Eltzschig, & Fredholm, 2013; Eltzschig, 2009; 
Fredholm, 2007).  Through its function as the major extracellular source of adenosine, CD73 is a 
key regulator of tissue homeostasis and pathophysiologic responses related to immunity, 
inflammation, and cancer, covered in recent reviews (Antonioli, Pacher, Vizi, & Hasko, 2013; 
Beavis, Stagg, Darcy, & Smyth, 2012; Colgan, Eltzschig, Eckle, & Thompson, 2006; Roberts, 
Lu, Rajakumar, Cowan, & Dwyer, 2013). The focus of this review is to highlight known and 




Structural and molecular features of CD73. Molecular and structural studies have 
revealed that CD73 is glycosylphosphatidylinositol (GPI)-anchored protein that is functionally 
coupled with another enzyme, ecto-apyrase (CD39), which supplies the AMP substrate for 
CD73(Antonioli, Pacher, et al., 2013). Characterization of the human CD73 protein using X-ray 
crystallography has revealed that human CD73 is a dimer and that its dimerization interface is 
formed via the C-terminal domain (K. Knapp et al., 2012). The crystal structure of CD73 from 
the T. thermophiles bacteria species differs from the human structure at the N-terminal metal ion-
binding domain and the C-terminal substrate-binding domain. While structurally the bacterial 
and human proteins are different, the ecto-nucleotidase function is evolutionarily conserved 
(Knapp, Zebisch, & Strater, 2012).    
Evidence for non-enzymatic CD73 functions. CD73 function and regulation differ 
between cell types with respect to phospholipase sensitivity, shedding from the cell membrane, 
and ability to trigger intracellular signals in response to antibody stimulation, which suggests a 
potential signaling function independent of adenosine (Airas et al., 1997). Indeed, several studies 
highlight important functions of CD73 that are independent of its activity as an AMPase, 
including: (i) T-cell activation via protein interactions to deliver a co-stimulatory signal (Resta & 
Thompson, 1997); (ii) promoting adhesion of lymphocytes to the endothelium (Airas et al., 
1995) by inducing integrin clustering; (Airas, Niemela, & Jalkanen, 2000) (iii) conferring 
resistance to apoptosis of leukemic cells via GPI-anchor-dependent mechanisms (Mikhailov et 
al., 2008); (iv) inducing phosphorylation of endothelial and lymphocyte proteins in response to 
antibody ligation (Airas et al., 1997; Dianzani et al., 1993); and inhibition metastasis of breast 
cancer cells after membrane clustering and internalization (Terp et al., 2013). Presently it is not 
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known whether these observations are linked to a common function, such as CD73 potentially 
functioning as a receptor for a putative ligand, which has yet to be defined.  
Physiological and disease relevance of CD73. CD73 is ubiquitously expressed in 
humans, but its expression pattern varies across tissues and cells types (Figure 1). CD73-
generated adenosine plays a pivotal role in several physiological functions including: epithelial 
ion and fluid transport, tissue barrier maintenance, hypoxia, ischemic preconditioning, and 
inflammation (Colgan et al., 2006). Mutations in NT5E leading to catalytically nonfunctional 
CD73 cause ACDC, a disease that manifests with symptomatic arterial and joint calcifications in 
humans (St Hilaire et al., 2011). ACDC has an autosomal recessive pattern of inheritance and is 
adult onset.  
The mouse Nt5e-/- knockout model recapitulates some, but not the full spectrum, of the 
human pathology (Li, Price, Sundberg, & Uitto, 2014). Part of the mechanism by which 
mutations of the human NT5E gene contribute to disease is attributed in part to defective 
intracellular trafficking of CD73 (Fausther, Lavoie, Goree, Baldini, & Dranoff, 2014).  Global 
deletion of the mouse gene (Nt5e) leads to hypoxia-induced vascular leakage in multiple tissues, 
most profoundly in the lung (Thompson et al., 2004).  The Nt5e-/- mice, which were generated 
and first described by Linda Thompson and her colleagues fifteen years ago (Thompson et al., 
2004) have been used in numerous studies since then to uncover a number of phenotypes, as 
described in Figure 2. The initial characterization of the Nt5e-/- mice provided the foundational 
knowledge to further examine CD73 in various pathophysiological states.  This review will 
address the current understanding of CD73 function and regulation landscape at the cell and 







CHAPTER 2: CD73 FUNCTIONS IN THE CARDIOVASCULAR SYSTEM 
CD73 expression and distribution in the cardiovascular system.  Robert Berne showed 
55 years ago that adenosine production in the heart is stimulated in response to hypoxia and 
proposed that adenosine mediates local metabolic control of coronary blood flow (the adenosine 
hypothesis) (Berne, 1963). A brief historical account of some of the studies (Eltzschig et al., 
2003; Koszalka et al., 2004) leading to the recognition of CD73 as a key player in the 
cardiovascular system was provided by Ray Olsson in 2004 (Olsson, 2004). Other relevant work 
on CD73 and purinergic signaling in the heart was highlighted in a review by Burnstock and 
Pelleg (Burnstock & Pelleg, 2015).  Here we focus on the most recent work regarding cell type 
specific functions of CD73 in the cardiovascular system.   
In the cardiovascular system CD73 is expressed on smooth muscle cells (Yang et al., 
2015), endothelial cells (M. Ohta et al., 2013; Pluskota et al., 2013), and resident lymphocytes 
(Bonner, Borg, Burghoff, & Schrader, 2012). The Human Protein Atlas reports moderate levels 
of CD73 protein expression on normal human smooth muscle cells, endothelial cells, and 
cardiomyocytes (Uhlen et al., 2015), whereas Bonner et al. noted lack of CD73 on these cell 
types in mouse heart (Bonner et al., 2013). It is possible that disruption of the tissue architecture 
during digestion and processing for cell sorting activated mechanical signaling to trigger 
downregulation of surface CD73 from non-immune cells in the latter study (Bonner et al., 2013). 
For example, hepatocytes in vivo express CD73, but this expression is dramatically 
downregulated during the process of liver digestion and cell isolation (Snider et al., 2013). One 
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potential molecular mechanism may be through the actions of the mechanosensitive cytoskeletal 
protein kindlin-2, a modulator of integrin signaling in endothelial cells and cardiomyocytes 
(Dowling et al., 2008) that regulates CD73 trafficking to the membrane (Pluskota et al., 2013). In 
the Bonner et al. study, the resident leukocyte population, in particular T cells had the highest 
level of CD73 per cell and highest proportion of CD73-positive cells. However, ~50% of the 
resident T cells expressed CD73, in contrast to almost ~90% of T cells in the circulation that 
were CD73 positive. Therefore, assessing functional contributions to CD73 on different cell 
types in the heart and vasculature will require additional studies utilizing cell type-specific 
deletion of CD73 in cells and in mice. The key functions of CD73 reported relate to supporting 
recovery after myocardial infarction (MI), protection during in heat failure (Quast, Alter, Ding, 
Borg, & Schrader, 2017), promoting atherosclerosis (Yang et al., 2015), supporting aortic valve 
function (Zukowska et al., 2017) and blocking arteriogenesis (Boring et al., 2013). We will 
highlight recent work related to the cell-specific roles of CD73 in MI below. 
Cell type-dependent roles of CD73 after myocardial infarction (MI). Healing and 
recovery of tissue function following myocardial infarction is dependent on T cell-expressed 
CD73, which decreases inflammation through the generation of adenosine (Borg et al., 2017). 
Specifically, circulating T cells invade the injured heart after infarction and upregulate 
expression of hydrolyzing enzymes that act on ATP, cAMP, and NAD, culminating in adenosine 
production via CD73. Activation of A2AR and A2BR leads to reduction in the release of 
inflammatory mediators. T cells from Nt5e-/- mice are skewed toward Th1 and Th17 types, 
resulting in increased levels of their respective pro-inflammatory cytokine products IFN-γ and 
IL-17 (Borg et al., 2017). When co-cultured with mesenchymal stem cells, monocytes upregulate 
CD73 expression in vitro and in vivo in post-MI swine heart (Monguio-Tortajada et al., 2017). 
6 
 
This promotes an anti-inflammatory state and implicates CD73 in the healing functions of 
mesenchymal stem cells.  
Interestingly, a functionally significant upregulation of CD73 on epicardium-derived cells 
(EPDCs) following MI promotes the release of pro-inflammatory cytokines and pro-fibrogenic 
matrix proteins (Hesse et al., 2017). EPDCs, which are normally quiescent in the adult heart, are 
activated and give rise to multiple cell types following ischemic heart injury. The increased 
production of CD73-generated adenosine from EPDCs leads to A2BR activation, which 
stimulates the release of pro-inflammatory cytokines (IL-6, IL-11, and VEGF) (Hesse et al., 
2017). Although the overall in vivo evidence thus far suggests a protective, anti-inflammatory 
function of CD73, a critical understanding of the cell-specific mechanisms for how CD73 
regulates cardiac remodeling or healing after MI may promote development of potential 

















CHAPTER 3: CD73 FUNCTIONS IN THE CENTRAL NERVOUS SYSTEM 
CD73 expression and distribution in the central nervous system (CNS). 
Immunohistochemical localization of CD73 in mouse brain performed in two independent 
studies revealed intense staining in the striatum (Augusto et al., 2013; Kulesskaya et al., 2013) as 
well as global pallidus, choroid plexus and meninges (Kulesskaya et al., 2013). Of note, these 
structures did not show any positive signal with an anti-CD73 antibody in brain sections from 
Nt5e-/- mice, establishing specificity of the assay (Kulesskaya et al., 2013). Biochemically CD73 
appears to contribute ~90% of the 5’-nucleotidase activity across the brain, but the spatial 
distribution and the identity of the predominant cell types that exhibit CD73 activity in the 
mouse brain was not determined (Kulesskaya et al., 2013). The Human Protein Atlas reports 
highest expression of CD73 in the cerebellum (Purkinje and granular cell layer) and cortical 
endothelial cells (Uhlen et al., 2015), which is in stark contrast to previous work in mouse brain 
reporting complete lack of 5’-nucleotidase activity in the granular layer of the cerebellum and 
blood vessels (Langer et al., 2008). Several potential factors may account for this discrepancy, 
including assay sensitivity (e.g. antibody detection versus enzymatic activity) and differences in 
CD73 distribution between mouse and human brain. The cell type specific distribution of CD73 
in the mouse spinal cord was characterized with the use of specific neuronal subtype markers, 
showing strong expression on L3-L5 dorsal root ganglion neuron membranes, particularly on the 
subset of neurons that express nociceptive neuron markers (IB4, Mrgprd, CGRP, and TRPV1) 
(Sowa, Taylor-Blake, & Zylka, 2010). Axon terminals in lamina II of the spinal cord express 
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CD73, along with another ecto-nucleotidase, prostatic acid phosphatase (PAP). Similar to CD73, 
PAP hydrolyzes AMP to produce adenosine and both proteins and their corresponding activities 
decrease in response to nerve injury (Sowa, Taylor-Blake, et al., 2010). Since the activities of 
CD73 and PAP enzymes are sensitive to the pH, Sowa et al. proposed that functional 
predominance of one enzyme may be relevant under certain conditions, such as during 
inflammation or tissue acidosis (Sowa, Taylor-Blake, et al., 2010). Multiple studies to date have 
implicated CD73 in major CNS functions, including locomotion and behavior  (Augusto et al., 
2013; Kulesskaya et al., 2013), memory functions and plasticity (Blundon et al., 2017; 
Zlomuzica, Burghoff, Schrader, & Dere, 2013), sleep regulation (Zielinski, Taishi, Clinton, & 
Krueger, 2012), thermoregulation (Muzzi et al., 2013), host-pathogen interactions during brain 
infection (Mahamed, Mills, Egan, Denkers, & Bynoe, 2012), inflammation (Mills et al., 2008; 
Petrovic-Djergovic et al., 2012; Xu et al., 2018), and nociception. We highlight several studies 
where the mechanisms of CD73 have been well described. 
CD73 controls locomotion. In the striatum CD73 is closely associated with the A2AR in 
the post-synaptic compartment, and this interaction appears to be important for controlling 
locomotion because Nt5e-/- mice have decreased locomotor activity compared to WT mice after 
repeated amphetamine administration, phenocopying A2AR knockout mice (Augusto et al., 
2013). In contrast, baseline locomotion in the Nt5e-/- mice is elevated when measured in the 
elevated plus maze, open field test, circadian activity test, and monitoring in the housing cages, 
although the mechanisms behind these observations were not investigated (Kulesskaya et al., 
2013). Therefore, the effect of CD73 on locomotion appears to be context specific, and likely 
mediated by the spatiotemporal dynamics of the signaling pathways over which CD73 exerts 
control, together with other ecto-nucleotidases and adenosine receptor subtypes.  
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Thalamic CD73 tunes the plasticity of the auditory cortex. The auditory cortex of adults, 
unlike newborns, lacks the plasticity required to tune neural circuitry upon passive exposure to 
auditory inputs from the environment (Kehayas & Holtmaat, 2017). Recently, Blundon et al. 
(Blundon et al., 2017) identified CD73-generated adenosine and subsequent A1R activation to be 
a key mechanism for age-dependent decline in auditory cortex plasticity. Genetic deletion of the 
A1Rs from the auditory thalamus of mature mice promoted plasticity of the auditory cortex after 
passive tone exposure (Blundon et al., 2017). Compared to neonates, thalamic expression of 
CD73 in mature mice was significantly elevated, which paralleled increased adenosine 
production (Blundon et al., 2017). In mature Nt5e–/– mice exposed to a pure tone there was 
induction in auditory cortex plasticity, and tone-exposed Nt5e–/– mice distinguished frequencies 
better than tone-naive Nt5e–/– mice (Blundon et al., 2017). These results may have implications 
for restoring cortical plasticity via CD73 manipulations in learning and other contexts, such as 
recovery after stroke.  
CD73 on tissue-resident cells regulates CNS inflammation. Given the central role of 
adenosine as an immunomodulator, several studies have addressed the function of CD73 in brain 
inflammation (Mills et al., 2008; Petrovic-Djergovic et al., 2012; Xu et al., 2018). Using genetic 
and pharmacological approaches, Petrovic-Djergovic and colleagues demonstrated a protective 
role of CD73 in neuroinflammation due to ischemic stroke (Petrovic-Djergovic et al., 2012). 
Specifically, Nt5e–/– mice were more susceptible to ischemic stroke injury, and the ischemic 
tissue had increased influx and activation of macrophages and pro-inflammatory markers, such 
as IL1-β, IL6, and TNF-α (Petrovic-Djergovic et al., 2012). This effect was reversed by 
administration of soluble CD73, suggesting that the effect was adenosine-mediated (Petrovic-
Djergovic et al., 2012). Furthermore, bone marrow transplantation experiments demonstrated 
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that the protective effect of CD73 stemmed from tissue-resident cells, as opposed to CD73 on 
circulating immune cells that infiltrated after the injury (Petrovic-Djergovic et al., 2012). While 
the specific role of CD73 on astrocytes has not been examined, it is possible that astrocytes play 
an key role in this model, since astrocytes contribute to CD73-generated adenosine (Chu, Xiong, 
& Parkinson, 2014) and control neuronal injury following ischemic stroke (Takano, Oberheim, 
Cotrina, & Nedergaard, 2009).  
Surprisingly, CD73 is pro-inflammatory in a mouse model of experimental autoimmune 
encephalomyelitis (EAE), which mimics inflammation associated with multiple sclerosis (Mills 
et al., 2008). Whereas WT mice displayed weak tail and partial hind limb paralysis and weak tail 
by 3 weeks of disease onset, the Nt5e-/- mice only had a weak tail and the disease did not worsen 
over time (Mills et al., 2008). Lymphocyte infiltration into the brain was significantly blunted in 
the Nt5e-/- mice, implicating CD73 as a facilitator for the entry of pathogenic T cells into the 
CNS (Mills et al., 2008). Similar to the stroke model, adoptive transfer studies demonstrated a 
role for CD73 on non-hematopoietic cells, potentially choroid plexus epithelial cells, which 
expressed CD73 in the WT mice (Mills et al., 2008). Modulation of blood-brain barrier function 
via CD73-generated adenosine and activation of A1R and A2AR receptors in one potential 
mechanism behind the increased lymphocyte infiltration and inflammation in the EAE model 
(Carman, Mills, Krenz, Kim, & Bynoe, 2011). Combined, these two studies demonstrate that 
CD73 can exert pro- or anti-inflammatory effects in the brain, depending on the specific 
inflammatory condition and the cell types involved, which is an important consideration for 
potential therapeutic applications of CD73 modulators in CNS inflammation.  
Neuronal CD73 regulates nociception. CD73 and two additional nucleotidases (PAP and 
tissue non-specific alkaline phosphatase) generate extracellular adenosine in the spinal cord to 
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regulate the function of pain sensing neurons (Street et al., 2013; Street & Zylka, 2011). A series 
of elegant studies on Nt5e-/- mice, utilizing supplementation with soluble mouse CD73 enzyme, 
demonstrated that CD73 plays a key role in regulating nociception in the mouse spinal cord 
(Sowa, Voss, & Zylka, 2010; Xu et al., 2018). Intrathecal administration of soluble mouse CD73 
protein elicited dose-dependent and long-lasting (2 days) antinociceptive effects in response to 
heat-induced pain (Sowa, Voss, et al., 2010). Similarly, soluble CD73 had antinociceptive effects 
in inflammatory and neuropathic pain models (Sowa, Voss, et al., 2010). At the molecular level, 
these effects were the result of adenosine-dependent A1R activation, since soluble CD73 did not 
produce antinociceptive effects in A1R-/- mice (Sowa, Voss, et al., 2010). The relative 
contribution of CD73 on hematopoietic cells versus neurons in the inflammatory pain models is 
not presently clear, because studies using bone marrow chimera have not been performed. 
However, upon spinal cord injury, CD73 promotes polarization of macrophages and microglia to 
the M2 anti-inflammatory phenotype, suggesting that immune cells may play at least a partial 















CHAPTER 4: CD73 FUNCTIONS IN THE LUNG 
CD73 expression and distribution in the lung. Together with tissue non-specific alkaline 
phosphatase, CD73 is known to be the major regulator of adenosine production on airway 
surfaces (Picher, Burch, Hirsh, Spychala, & Boucher, 2003). Human Protein Atlas reports high 
CD73 expression on human pneumocytes, which exhibit both cytoplasmic and membrane 
distribution. CD73 is also expressed and enzymatically active on primary human nasal and 
bronchial epithelial cells where it controls proper cilia beating frequency and ion transport, thus 
demonstrating its role in mucociliary clearance which is protective in the development of 
infectious lung diseases (Picher et al., 2003). 
 
CD73 promotes maintenance of tissue barrier function in the lungs during hypoxia 
and hyperoxia. One of the earliest phenotypes reported using the global CD73-null mice showed 
vascular leakage in response to normobaric hypoxia in multiple tissues, which was most 
pronounced in the lung (Thompson et al., 2004). Hypoxia-induced vascular leakage was only 
partially reversed by adenosine receptor agonists and administration of soluble CD73, leaving 
open the possibility for additional non-enzymatic functions of CD73 that may be compromised 
in the Nt5e-/- mice. In humans, acute respiratory distress syndrome (ARDS) leads to pulmonary 
vascular leakage and clinical trials utilizing recombinant IFN-β1 (FP-1201) as a treatment 
strategy have revealed the potential to induce CD73 expression in the lungs and reduce mortality 
in patients with ARDS (Bellingan et al., 2017; Bellingan et al., 2014). Specifically, these studies 
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demonstrated that CD73 was significantly upregulated ex vivo in peri-bronchiolar vessels of 
cultured human lung tissue in response to IFN-β1 treatment, and that IFN-β1 attenuated 28-day 
mortality (8% of IFN-β1 treated patients died, versus 32% in the control group) (Bellingan et al., 
2014). CD73 is highly upregulated in response to hyperoxia, and Nt5e-/-  mice develop more 
severe pulmonary edema during hyperoxic lung injury. The latter effect, which is also 
phenocopied in A2AR-/- mice, is attributed to loss of barrier function in the setting of decreased 
adenosine production (Davies et al., 2014). 
CD73 protects against lung infection, inflammation and fibrosis. CD73-null mice 
exhibit increased weight loss and inflammation in response to intratracheal administration of 
lipopolysaccharide (LPS) (Ehrentraut et al., 2013) concomitant with significant transcriptional 
upregulation of TNFα, IL-1β, and IL-6. These effects were attributed to adenosine generation by 
regulatory T cells and the phenotypes of the Nt5e-/-  mice were partially rescued by 
administration of soluble CD73. Deletion of CD73 does not affect baseline adenosine levels in 
the lungs, but it prevents adenosine production in response to bleomycin treatment (Volmer, 
Thompson, & Blackburn, 2006). Consequently, bleomycin treated Nt5e-/-  mice exhibit enhanced 
inflammation, collagen production, and more severe fibrosis, which were attenuated by 
intranasal administration of exogenous nucleotidase. Treatment with the CD73 inhibitor APCP 
or the non-selective adenosine receptor antagonist CGS 15943 caused increased susceptibility of 
mice to S. pneumoniae lung challenge, although the effect was more pronounced upon CD73 
inhibition (Bou Ghanem et al., 2015).  
CD73 may contribute to asthma pathogenesis. Although CD73 function is known to be 
critical for regulating airway diseases, its involvement in asthma is poorly understood. CD73 
expression is upregulated in the lungs of ovalbumin-treated mice (Bentley et al., 2010), and a 
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single study  reported that Nt5e-/-  mice are protected against ovalbumin-induced airway 
hyperresponsiveness and inflammation (Schreiber, Castrop, & Kunzelmann, 2008). To our 
knowledge, CD73 expression and activity in asthma patients has not been examined, with the 
exception of demonstration that BAL fluid from a patient with asthma contained a subpopulation 
of CD73-expressing cells that were thought to represent a mesenchymal progenitor cell type able 
to differentiate into fat, bone or cartilage (Bentley et al., 2010). Whether CD73 is simply a 
marker of these cells, or an active player in MSC-mediated regulation of inflammatory and 

















CHAPTER 5: CD73 FUNCTIONS IN THE KIDNEY 
CD73 expression and distribution in the kidney. The enzymatic activity of CD73 in the 
kidneys is nearly highest of all the tissues in the body (Colgan et al., 2006; Thompson et al., 
2004).  In rat kidneys CD73 decorates the apical membranes of the proximal convoluted tubule, 
intercalated cells of the distal nephron, and is also expressed in the peritubular space (Shirley, 
Vekaria, & Sevigny, 2009).  Similar to other tissues, renovascular function is under the control 
of adenosine produced by both CD73 and TNAP (Jackson, Cheng, Verrier, Janesko-Feldman, & 
Kochanek, 2014). 
CD73 regulates renal ischemia-reperfusion (I/R) injury. Adenosine receptor signaling 
promotes renal I/R injury, based on findings that A2BR-/- are protected in I/R (Grenz et al., 2008).  
Additionally, genetic deletion or pharmacological inhibition of CD73, CD39, or both in mice 
revealed that CD73 and CD39 exacerbate I/R injury (Rajakumar et al., 2010; Roberts et al., 
2013).  Proximal tubular CD73 in particular is important for regulating renal I/R injury (Sung et 
al., 2017).  In contrast to this reported injury-promoting role, CD73 plays a protective role in the 
context of isoflurane-mediated protection against renal I/R injury. Mice pretreated with a CD73 
inhibitor or an adenosine receptor antagonist are insenstitive to this isofluorane-mediated 
protection (Kim et al., 2013). 
CD73 regulates hypertension-associated renal injury.  CD73 is upregulated and 
generates adenosine in a model of hypertensive nephropathy induced by angiotensin II (Zhang et 
al., 2013).  CD73-generated adenosine promotes hypertension associated with chronic kidney 
disease through A2BR, which is driven by hypoxia-inducible factor-α (Zhang et al., 2013).  In 
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contrast to this hypertension promoting role, CD73 is protective through A2BR signaling in the 
context of diabetic neuropathy in the mouse kidney (Tak et al., 2014).  CD73 is also protective in 
the rat kidney in a diabetic neuropathy model induced via streptozotocin (Taskiran et al., 2016).  
Furthermore, pharmacological antagonists for A3R alleviate fibrosis driven by diabetic 
neuropathy in rat kidneys (Kretschmar et al., 2016).   
Other functions of CD73 in the aging and injured kidney. CD73 knockout mice exhibit 
spontaneous proteinuria and renal functional deterioration as they age because of an autoimmune 
inflammation affecting the glomerular endothelium (Blume et al., 2012). Pharmacological 
inhibition or genetic deletion of CD73 in mice leads to more severe kidney injury in sepsis 
models (via cecal ligation) compared to WT mice (Hasko et al., 2011).  Polymorphisms in NT5E  
have been implicated in the development of calcific uremic arteriolopathy in dialysis patients, 



















CHAPTER 6: CD73 FUNCTIONS IN THE LIVER 
CD73 expression and distribution in the liver. In the normal human liver CD73 is 
expressed  on the apical membrane of hepatocytes as well as endothelial cells, which express 
CD73 at lower levels compared to hepatocytes (Matsuura, Eto, Kato, & Tashiro, 1984). During 
myofibroblast differentiation of activated hepatic stellate cells in culture there is transcriptional 
upregulation of NT5E (Fausther, Sheung, Saiman, Bansal, & Dranoff, 2012), but this is in 
contrast to significant downregulation observed in human liver fibrosis, regardless of etiology or 
severity (Snider et al., 2013). CD73 recently has emerged as a critical regulator of hepatocyte 
responses to different forms of injury (Hart et al., 2008; Peng et al., 2009; Peng et al., 2008; 
Snider et al., 2013), illuminating common disease mechanisms that may be exploited 
therapeutically.  
CD73 regulates hepatic fibrosis. Nt5e-/- mice were previously reported to be resistant to 
hepatic fibrosis (Peng et al., 2008) induced by carbon tetrachloride (CCl4) or thioacetamide 
(TAA), which is surprising because genetic or pharmacologic inhibition of adenosine A2AR 
causes exacerbated liver injury in inflammation and fibrosis injury models (Chan et al., 2006; A. 
Ohta & Sitkovsky, 2001). If adenosine has a protective role in hepatic fibrosis, then removal of 
the major enzymatic source of extracellular adenosine (CD73) should exacerbate the pathology, 
but the opposite is seen. One of several possible interpretations is that constitutive Nt5e deletion 
eliminated an adenosine-independent function of CD73 that promotes hepatic fibrosis. If that is 
the case, it may also help explain the resistance of CD73-/- mice to ethanol-induced steatosis 
(Peng et al., 2009) and Mallory-Denk body-associated hepatocellular injury (Snider et al., 2013) 
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CD73 regulates hepatic steatosis. An early phenotype of ethanol consumption that 
damages the liver is the development of hepatic steatosis, which is the accumulation of fat in the 
liver.  WT mice develop hepatic steatosis while mice lacking CD73 or adenosine A1 or A2B 
receptors are protected after alcohol treatment (Peng et al., 2009).  Additionally, in vitro studies 
using cultured murine hepatocyte cell lines supported these findings, suggesting adenosine 
generated by ethanol metabolism plays an important role in ethanol-induced hepatic steatosis 
(Peng et al., 2009).  These data demonstrate that CD73 is important in the role acute liver 
diseases, and it would be beneficial to determine if CD73 can mediate the progression into 
chronic liver diseases.  
CD73 regulates hepatic fibrosis. Several studies have shown the importance of CD73 in 
chronic liver disease models, such as liver fibrosis.  For example, studies utilizing chemical 
injury (carbon tetrachloride or thioacetamide treatment) for the induction of liver fibrosis in mice 
illustrated that Nt5e-/- mice were protected from the development of liver fibrosis or cirrhosis, 
while WT mice developed fibrosis and cirrhosis(Peng et al., 2008).  Liver fibrosis is 
accompanied by the activation of liver myofibroblasts, that typically originate from hepatic 
stellate cells and portal fibroblasts (Iwaisako et al., 2014).  Although CD73 is expressed in 
murine liver fibrosis models and liver myofibroblasts, NT5E is transcriptionally down-regulated 
via mediation by Elf2-like transcription factors in mouse-activated liver myofibroblasts 
(Fausther, Lavoie, Goree, & Dranoff, 2017).  Conversely, other studies have shown NT5E 
transcriptional up-regulation through promoter response elements for SP1 and SMAD 
transcription factors (Fausther et al., 2012).  
CD73 regulates hepatocyte injury. In the context of hepatic ischemia, CD73 is induced 
at the transcriptional and protein level (Hart et al., 2008) and serves a protective function. Nt5e-/- 
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mice develop more severe injury, which can be reversed by administration of soluble enzyme 
(Hart et al., 2008).  Based on this a proposed method to elicit hepatoprotection during hepatic 
ischemia/reperfusion would be to inhibit adenosine uptake (Zimmerman et al., 2013).  
Equilibrative nucleoside transporters (ENTs) are responsible for the uptake of adenosine, and 
transcriptional downregulation of ENTs are correlated with ischemia and reperfusion during 
human liver transplantation and during murine liver ischemia and reperfusion (Zimmerman et al., 
2013).  Ultimately, these studies provide the framework for potential therapies to manage 
ischemia and reperfusion by maintaining extracellular adenosine levels.  
The formation of hepatocyte Mallory-Denk bodies (MDBs), which are aggregates of 
keratins 8 and 18 (K8/K18), ubiquitin, and the ubiquitin-binding protein p62, are generally 
associated with the development of chronic liver diseases (Snider et al., 2013).  We previously 
have demonstrated that CD73 modulates the formation of MDBs in a strain-related manner 
(Snider et al., 2013).  In mice livers that lacked CD73, chemical-induced liver injury (in the form 
of MDBs) was prevented, but this protection was not observed in WT mice under the same 















CHAPTER 7: CD73 FUNCTIONS IN THE IMMUNE SYSTEM 
CD73 expression on immune cells. The role of CD73 has been most extensively studied 
in context of the immune system (Antonioli, Pacher, et al., 2013; Resta, Yamashita, & 
Thompson, 1998). CD73 is expressed in macrophages, monocytes, dendritic cells, and 
neutrophils (Antonioli, Pacher, et al., 2013; Resta & Thompson, 1997; Resta et al., 1998; Saze et 
al., 2013). It is highly expressed on lymphocytes, particularly T cells and B cells (Conter, Song, 
Shlomchik, & Tomayko, 2014; Kaku, Cheng, Al-Abed, & Rothstein, 2014; Saze et al., 2013). In 
T cells, thymic γδ lineage commitment relies on T cell receptor ligand-induction of CD73 
expression.  
CD73 regulates immune cell migration. The expression of CD73 on the cell surface has 
been shown to play a key role in immune cell migration in response to inflammatory stimuli. 
Upon LPS treatment in mice, CD73 on endothelial cells restricts the migration of lymphocytes 
into the draining lymph nodes through the activation of A2Rs (Takedachi et al., 2008; Thompson 
et al., 2008). Mills et al showed that the infiltration of T cells into the central nervous system 
during experimental autoimmune encephalomyelitis in mice is regulated by CD73 that is highly 
expressed in the choroid plexus (Mills et al., 2008). In the absence of CD73 in the immune cells, 
the number of infiltrating lymphocytes increases and further exacerbates the inflammation or 
condition. CD73 KO mice that were infected with Toxoplasma gondii showed a higher 
propensity for neutrophil and T cell infiltration, inducing an immune-mediated pathology 
(Mahamed, Toussaint, & Bynoe, 2015). The administration of the adenosine receptor agonist, 
NECA attenuated the severity of inflammation, suggesting a key role of the adenosine-
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generating function of CD73. Similarly, CD4+ T cells that lack CD73 produce a stronger immune 
response against bacterial infection, and generate pro-inflammatory cytokines like TNFα, IFN γ, 
IL17A, and keratinocyte chemoattractant.  
CD73 regulates chronic inflammation. In the germinal center, follicular dendritic cells 
interact with B cells via CD73 and induce maturation (Airas & Jalkanen, 1996). Interestingly, B1 
cells, which are a part of the humoral response, express a 5-fold increase in CD73 compared to 
the adaptive immune B2 cells (Conter et al., 2014). Allard et al further showed that the lack of 
CD73 and subsequent adenosine signaling in B1 cells delayed isotype switching from the 
primary response IgM antibody to the pro-inflammatory IgG3 antibody (Allard, Charlebois, 
Gilbert, Stagg, & Chrobak, 2018). However, this delay in isotype switching did not alter the 
protective response to infection. In a chronic state of inflammation, CD73-expressing T follicular 
helper cells regulate the differentiation and maintenance of B cells in to plasma cells, suggesting 
an important role of CD73 in establishing humoral immunity (Conter et al., 2014). While 
macrophages and monocytes express cell surface CD73 in both mice and humans, their 
polarization towards a pro-inflammatory M1 or anti-inflammatory M2 phenotype is independent 
of CD73 (Eichin, Laurila, Jalkanen, & Salmi, 2015).  
Genetic deletion of CD73 promotes T cell expansion, and production of pro-
inflammatory cytokines IFNγ and IL-6 in a mice model of graft vs host disease (GvHD) 
(Tsukamoto et al., 2012). Specifically, blocking the enzymatic activity of CD73 induced a 
stronger alloreactive T cell activity, suggesting that the adenosine-generating function is 
important in the progression of GvHD (Wang et al., 2013). Thus, these suggest an important 
function of CD73 in the immune cells in attenuating the severity of inflammation or condition 





CHAPTER 8: CD73 FUNCTIONS IN OTHER TISSUES AND CELL TYPES 
Gastrointestinal system. CD4+ T cells that lack CD73 produce a stronger immune 
response against bacterial infection, and generate pro-inflammatory cytokines like TNFα, IFN-γ, 
IL17A, and keratinocyte chemoattractant. This type of cytokine milieu resulted in more severe 
Helicobacter felis-induced gastritis or murine salmonellosis compared to the WT mice due to the 
failure of T regulatory cells lacking CD73 to attenuate inflammation. However, there was a 
significant enhancement of bacterial clearance in CD73 KO mice that were infected with H. felis 
or Salmonella (Alam et al., 2014; Alam et al., 2009). CD73 KO mice also exhibited a more 
severe condition of experimental inflammatory colitis compared to WT mice (Kaku et al., 2014). 
Upon adoptive transfer of CD73-expressing B1 cells from WT mice to CD73 KO mice, the 
disease severity was reduced (Kaku et al., 2014).  
Bone. The role of adenosine signaling in the development and differentiation of bone 
tissue, osteoblasts, and osteoclasts has been implicated in several studies.  For example, a study 
demonstrated that adenosine receptor activation induced mitogenesis and triggered a protective 
response in regard to cell death (Fatokun, Stone, & Smith, 2006; Shimegi, 1998).  Additionally, 
in human primary osteoblast cells it was shown that pharmacological activation of adenosine 
receptors promoted proliferation, and proliferation was halted with antagonism (Costa et al., 
2011). CD73 is a known marker of osteochondroprogenitor cells, which readily form bone after 
transplantation (Singh et al., 2015) and CD73-null mice develop bone deficiencies, such as 
osteopenia (Takedachi et al., 2012).  Furthermore, in vitro studies using MC3T3-E1 cells 
demonstrated CD73-generated adenosine signals through the adenosine A2B receptor to 
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modulate osteoblast differentiation.  Recently, it was demonstrated that CD73-generated 
adenosine in human amniotic fluid stem cells enhances osteogenic potential via TGFβ induction 
(Hau et al., 2017).  Overall, CD73 and CD73-generated adenosine are important in the process of 
bone development and growth. In terms of pathologic conditions, CD73-deficient mice are 
significantly more susceptible to developing collagen-induced arthritis compared to wild-type 
mice (Chrobak et al., 2015). In the absence of CD73, there is enhanced production of 
proinflammatory cytokines in the joints and augmented Th1 T cell responses, leading to joint 
destruction. Importantly, using bone marrow transplants it was shown that the protective activity 
of CD73 originated from nonhematopoietic cells (Chrobak et al., 2015).  
Inflammation of the eye. CD73 marks an intermediate stage in γδ T cells from which 
their ability to express effector genes IFNγ or IL-17 is resolved (Coffey et al., 2014). Related to 
this function, it was reported that CD73 expression on γδ T cells is dynamically regulated during 
experimental autoimmune uveitis (EAU) and that low CD73 expression on γδ T cells correlated 
with enhanced Th17 response-promoting activity. Mice lacking CD73 showed decreased 
susceptibility to developing EAU (Liang et al., 2016). 
Reproductive tissues. In CD73-deficient mice, it was demonstrated that CD73-generated 
adenosine is important to initiate and maintain penile erections (Wen et al., 2011).  In humans, 
the expression of ecto-nucleotidases, such as CD73, fluctuates in concert with the menstrual 
cycle and changes after menopause in the endometrium (Aliagas et al., 2013).   
Skin and Muscle. Nt5e-/- mice have lower susceptibility to developing bleomycin-
induced skin fibrosis (Fernandez et al., 2013). This response, also seen in the CD39-deficient 
mice, was associated with reduced expression of the profibrotic mediators, TGF-β1 and 
connective tissue growth factor, and decreased myofibroblast cell populations (Fernandez et al., 
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2013).  In Nt5e-/- mice that were fed a high fat diet, CD73 plays a protective role in the 
development of dyslipidemia and intramyocellular lipid accumulation in the muscle of mice 
(Burghoff et al., 2013).  Ultimately, CD73 function is critical in various tissues and processes in 
the body, therefore, it is essential to potentially exploit CD73 and adenosine signaling in the 









Figure 1. Relative levels of CD73 protein expression across human organ systems and 
tissues. The expression data on CD73 (Gene: NT5E) were collected from the Human Protein 
Atlas Project (https://www.proteinatlas.org/). Note that CD73 is ubiquitous and abundantly 





Figure 2. Reported phenotypes of the CD73 knockout mice. Unless otherwise specified, all 
studies utilized the whole body knockout model. Green upward pointing arrow denotes that the response 
was elevated in the CD73 knockout mouse; red downward arrow denotes that the response was decreased 
in the CD73 knockout mouse. In cases where conditional knockouts (cKO) were used, this is specified in 
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